CA2825252C - Compositions of an antithrombin activator and a thrombin inhibitor for use in cell transplantation - Google Patents

Compositions of an antithrombin activator and a thrombin inhibitor for use in cell transplantation Download PDF

Info

Publication number
CA2825252C
CA2825252C CA2825252A CA2825252A CA2825252C CA 2825252 C CA2825252 C CA 2825252C CA 2825252 A CA2825252 A CA 2825252A CA 2825252 A CA2825252 A CA 2825252A CA 2825252 C CA2825252 C CA 2825252C
Authority
CA
Canada
Prior art keywords
cells
combination
pharmaceutical composition
liver
heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2825252A
Other languages
English (en)
French (fr)
Other versions
CA2825252A1 (en
Inventor
Xavier STEPHENNE
Etienne Sokal
Mustapha Najimi
Stephane Eeckhoudt
Cedric Hermans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Catholique de Louvain
Original Assignee
Université Catholique de Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Catholique de Louvain filed Critical Université Catholique de Louvain
Publication of CA2825252A1 publication Critical patent/CA2825252A1/en
Application granted granted Critical
Publication of CA2825252C publication Critical patent/CA2825252C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2825252A 2011-01-25 2012-01-25 Compositions of an antithrombin activator and a thrombin inhibitor for use in cell transplantation Expired - Fee Related CA2825252C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11152119 2011-01-25
EP11152119.1 2011-01-25
PCT/EP2012/051157 WO2012101181A1 (en) 2011-01-25 2012-01-25 Compositions and methods for cell transplantation

Publications (2)

Publication Number Publication Date
CA2825252A1 CA2825252A1 (en) 2012-08-02
CA2825252C true CA2825252C (en) 2018-10-16

Family

ID=45607724

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2825252A Expired - Fee Related CA2825252C (en) 2011-01-25 2012-01-25 Compositions of an antithrombin activator and a thrombin inhibitor for use in cell transplantation

Country Status (12)

Country Link
US (3) US20130302291A1 (enExample)
EP (1) EP2667878B1 (enExample)
JP (1) JP6012629B2 (enExample)
CN (1) CN103402527B (enExample)
CA (1) CA2825252C (enExample)
DK (1) DK2667878T3 (enExample)
ES (1) ES2573522T3 (enExample)
IL (1) IL227529A0 (enExample)
PL (1) PL2667878T3 (enExample)
PT (1) PT2667878E (enExample)
SG (1) SG192124A1 (enExample)
WO (1) WO2012101181A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573522T3 (es) 2011-01-25 2016-06-08 Université Catholique de Louvain Composiciones y métodos para el trasplante celular
ES2726802T3 (es) 2012-01-25 2019-10-09 Univ Catholique Louvain Composiciones y métodos para el trasplante celular
EP2943206A4 (en) * 2013-01-12 2017-01-04 Cesca Therapeutics Inc. Rapid infusion of autologous bone marrow derived stem cells
SG10201906304TA (en) * 2013-03-15 2019-08-27 Miromatrix Medical Inc Use of perfusion decellularized liver for islet cell recellularization
JP6474394B2 (ja) 2013-07-05 2019-02-27 ユニベルシテ カトリック ドゥ ルーベン ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用
BR102013033827B1 (pt) * 2013-12-27 2021-09-08 Regenera - Medicina Veterinária Avançada Ltda. Concentrado multipotente e imunocompatível de células-tronco e biofármaco e forma de dosagem que o compreendem
WO2016198578A1 (en) * 2015-06-11 2016-12-15 Universiteit Maastricht Method for preventing transplant failure in a host.
CN106995796A (zh) * 2016-01-26 2017-08-01 李建业 基于细胞因子的细胞处理方法、试剂盒及冻干粉
EP3591037A4 (en) * 2017-03-03 2020-11-11 Rohto Pharmaceutical Co., Ltd. MESENCHYMATIC STEM CELL AND THERAPEUTIC AGENT AGAINST LIVER DISEASES
KR20200028391A (ko) 2017-06-12 2020-03-16 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 세포 생착용 패치 이식편 조성물
JP7264589B2 (ja) * 2017-12-25 2023-04-25 株式会社 資生堂 トロンビンの抑制作用を指標とした皮膚状態改善剤のスクリーニング方法、及びトロンビン作用阻害剤を含む皮膚状態改善剤
WO2019241499A1 (en) 2018-06-13 2019-12-19 Miromatrix Medical Inc. Fistula filler and deployment system
CN113677790B (zh) * 2019-03-26 2024-05-24 普罗米瑟拉疗法公司 用于治疗慢加急性肝衰竭的成体肝祖细胞
CN112608890B (zh) * 2020-12-17 2024-08-20 山东佰鸿干细胞生物技术有限公司 一种防止间充质干细胞粘连的培养方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9010552D0 (en) 1990-05-10 1990-07-04 Erba Carlo Spa Method for the recombinant production of hirudins and novel hirudins
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
GB0014136D0 (en) 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
DE10202982A1 (de) 2002-01-26 2003-07-31 Augustinus Bader Verfahren und Vorrichtung zum Einbringen von lebenden Zellen in eine biologische Körperflüssigkeit
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
JP2009508650A (ja) * 2005-09-21 2009-03-05 ダスク テクノロジーズ， エルエルシー 臓器および組織機能のための方法および組成
CA2634510C (en) * 2005-12-21 2018-01-09 Universite Catholique De Louvain Isolated liver stem cells
ES2573522T3 (es) 2011-01-25 2016-06-08 Université Catholique de Louvain Composiciones y métodos para el trasplante celular
ES2726802T3 (es) 2012-01-25 2019-10-09 Univ Catholique Louvain Composiciones y métodos para el trasplante celular

Also Published As

Publication number Publication date
IL227529A0 (en) 2013-09-30
JP2014508138A (ja) 2014-04-03
EP2667878B1 (en) 2016-03-30
SG192124A1 (en) 2013-08-30
EP2667878A1 (en) 2013-12-04
CN103402527B (zh) 2016-04-20
US10039789B2 (en) 2018-08-07
WO2012101181A1 (en) 2012-08-02
US10478459B2 (en) 2019-11-19
PL2667878T3 (pl) 2016-10-31
PT2667878E (pt) 2016-06-03
US20130302291A1 (en) 2013-11-14
CA2825252A1 (en) 2012-08-02
US20170354723A1 (en) 2017-12-14
US20170042940A1 (en) 2017-02-16
JP6012629B2 (ja) 2016-10-25
DK2667878T3 (en) 2016-06-27
CN103402527A (zh) 2013-11-20
ES2573522T3 (es) 2016-06-08

Similar Documents

Publication Publication Date Title
US10039789B2 (en) Compositions and methods for cell transplantation
EP2806879B1 (en) Compositions and methods for cell transplantation
EP3091991B1 (en) Immunomodulatory compositions
EP3515460B1 (en) Macrophage-based therapy for use in the treatment of acute liver injury
CN104703612B (zh) 包含溶剂/去污剂处理过的血浆(s/d血浆)的制剂及其用途
CN113677790B (zh) 用于治疗慢加急性肝衰竭的成体肝祖细胞
Liuwantara et al. Characterizing the mechanistic pathways of the instant blood-mediated inflammatory reaction in xenogeneic neonatal islet cell transplantation
US20190083542A1 (en) Adipose tissue-derived stem cells from transgenic porcine animals for veterinary use
EP3947645A1 (en) Adult liver progenitor cells for treating non-alcoholic fatty liver disease
JP7523441B2 (ja) Ｈｌａ－ｅを発現する肝臓前駆細胞を含む細胞組成物
den Tierkliniken Comparative Characterization of Human and Equine Mesenchymal Stromal Cells: A Basis for Translational Studies in the Equine Model

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161122

MKLA Lapsed

Effective date: 20210125